Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «РОНЦ им. Н.Н. Блохина» 115478, Россия, г. Москва, Каширское шоссе, д.23
PET/CT with 18F-FDG and 18F-choline in the diagnosis of hepatocellular cancer mixed with cholangiocellular cancer (case report)
*Tulin P.E. – MD Dolgushin M.B. – MD, PhD, professor Patiutko U.I. – MD, PhD, professor Shiryaev S.V. – MD, PhD, professor Odzharova A.A. – MD, PhD Vihrova N.B. – MD, postgraduate Moroz E.A. – MD, PhD Medvedeva B.M. – MD, PhD Romanova K.A. – MD, postgraduate
Federal State Budget Institution «N.N. Blokhin Russian Cancer Research Center» under the Russian Academy of Medical Sciences 24, Kashirskoye Shosse, Moscow, Russian Federation, 115478
ABSTRACT: Aim: was to estimate the diagnostic value of PET with 18F-Choline and 18F-FDG in case of mixed hepatocellular (HCC) and cholangiocellular cancer (CCC). Materials and methods: PET/CT with 18F-Choline and 18F-FDG was performed on 70 years old patient, with diagnosed hepatobilliary cancer. CT scan and MRI with intravenous contrast-enhanced, histological and immunohistochemical study of postoperative material (right-sided hemihepatectomy) were also performed. Results: difference in the accumulation of 18F-Choline and 18F-FDG in some areas of mixed hepatocellular and cholangiocellular cancer was detected: in the field of cholangiocellular cancer and in the field of poorly differentiated hepatocellular cancer. Conclusions: 18F-choline has a low diagnostic value in the detection of cholangiocellular cancer and poorly differentiated HCC, in contrast to 18F-FDG, whereas at high differentiated HCC study, 18F-choline is more preferable. Diagnostic value of 18F-FDG at high differentiated HCC is extremely low.
Список исп. литературыСкрыть список 1. Патютко Ю.И., Сагайдак И.В., Чучуев Е.С. Гепатоцеллюлярный рак печени. Бюллетень медицинских интернет-конференций. 2011;1:35–61. Patjutko Ju.I., Sagajdak I.V., Chuchuev E.S. Gepatocelljuljarnyj rak pecheni [Hepatocellular cancer]. Bjulleten' medicinskih internet-konferencij. 2011;1: 35–61 [In Russ]. 2. Чиссов В.И. Онкология. М.: Гэотар-Медиа. 2007; С. 391–399 Chissov V.I. Onkologija [Oncology]. M.: Gjeotar-Media. 2007; 391–399 [In Russ]. 3. Суконко О.Г. Гепатоцеллюлярный рак. Алгоритм диагностики и лечения злокачественных новообразований. М.: Медиа Сфера. 2012; 127–135. Sukonko O.G. Gepatocelljuljarnyj rak. Algoritm diagnostiki i lechenija zlokachestvennyh novoobrazovanij[Hepatocellular cancer. Algorithm of diagnostics and treatment of malignant neoplasms] M.: Media Sfera. 2012; 127–135 [In Russ]. 4. Bosh F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Semin. Liver dis., vol.19. 1999; 271–285. 5. Beasley R.P., Hwang L.Y. Overview on the epidemiology of hepatocellular carcinoma. Viral hepatitis and liver disease. 1991; 532–535. 6. Huo T.I., Lee S.D., Wu J.C. For hepatocellular carcinoma: look for a perfect classification system. J. Hepatol. 20–4; .40(6): 1041–1042. 7. Barazani Y., Hiatt J.R., Tong M.J. et al. Сhronic viral hepatitis and hepatocellular carcinoma. World J. Surg. 2007; 31: 1245–250. 8. Jeong S., Aviata H., Katamura Y. Low-dose intermittent interferon — alpha-therapy for HCV — related liver cirrosis after curative treatment of hepatocellular carcinoma. World J. Gastroenterology. 2007;113; 5188–5195. 9. Зогот С.Р., Акберов Р.Ф. Гепатоцеллюлярный рак (эпидемиология, лучевая диагностика, современные аспекты лечения). Лекции для врачей общей практики, онкология, практическая медицина, хирургия. 2013; 112–115. Zogot S.R., Akberov R.F. Gepatocelljuljarnyj rak (jepidemiologija, luchevaja diagnostika, sovremennye aspekty lechenija). Lekcii dlja vrachej obshhej praktiki, onkologija, prakticheskaja medicina, hirurgija [Hepatocellular cancer (epidemiology, radiodiagnostics, modern aspects of treatment). Lectures for general practice doctors, oncology, practical medicine, surgery]. 2013; 112–115 [In Russ]. 10. Майстренко Н.А., Шейко С.Б., Алентьев А.В. Холангиоцеллюлярный рак (особенности диагностики и лечения). Практическая онкология. 2009; 9(4): 229–236. Majstrenko N.A., Shejko S.B., Alent'ev A.V. Holangiocelljuljarnyj rak (osobennosti diagnostiki i lechenija) [Cholangiocellular cancer (features of diagnostics and treatment)]. Prakticheskaja onkologija. 2009; 9(4): 229–236 [In Russ]. 11. Ward J., Robinson P. How to detect hepatocellular carcinoma in cirrhosis. Eur. Radiology. 2002; 2258–2273. 12. Zhang F., Chen X.-P., Zhang W. et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008; 52: 224–232. 13. Caturelli E., Pompili M. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients. Radiology. 2001; 337–342. 14. Matsui O., Kadoya M., Kameyama T. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991; 493–497. 15. Xu H.X., Liu G.J., Lu M.D. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J. Clin Ultrasound. 2006; 261–272. 16. Lencioni R., Piscaglia F. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal Of Hepatology. 2008; 48: 848–857. 17. Prokop M. Spiral and multislice computed tomography of the body. Georg Thieme Verlag. 2003; Р 234–240. 18.Tiferes D., D’ippolito G. Liver neoplasms: imaging characterization. Radiol. Bras. 2008; 41(2): 119–127. 19. Медведева Б.М., Лукьянченко А.Б. Возможности МРТ в диагностике гепатоцеллюлярного рака у пациентов с циррозом печени. Rejr. 2013; 3(2): 63. Medvedeva B.M., Luk'janchenko A.B. Vozmozhnosti MRT v diagnostike gepatocelljuljarnogo raka u pacientov s cirrozom pecheni [Possibilities of MRI in diagnostics of hepatocellular cancer in patients with liver cirrhosis ]. Rejr. 2013; 3(2): 63 [In Russ]. 20. Jeong Y., Yim N., Kang H. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. Ajr. 2005; 1024–1032. 21. Lee M.H., Kim S.H., Park M.J., Park C.K. Gadoxetic acid–enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Ajr. 2011; 197: 868–875. 22. Nasu K., Kuroki Y., Tsukamoto T. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. Ajr. 2009; 193: 438–444. 23. Ferucci J. MRI of the liver. Amer. J. Roentgenol. 1985; 147: 1103–1116. 24. Yamamoto Y., Nishiyama Y. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. The journal of nuclear medicine. 2008; 49(8): 1245–1248. 25. Hwang K.H., Choi D.-J. Evaluation of patients with hepatocellular carcinomas using [11C]-acetate and [18F]-FDG PET/CT: a preliminary study. Radiation and isotopes. 2009; 67: 1195–1198. 26. Talbot J., Gutman F. PET/CT in patients with hepatocellular carcinoma using [18F]- fluorocholine: preliminary comparison with [18F]-FDG PET/CT. Eur. J. Nucl. Med. 2006; 33: 1285–1289. 27. Сhang M., Seungmin B. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of gastroenterology and hepatology. 2008; 23: 759–765. 28. Kluge R., Schmidt F., Caca K. Positron emission tomography with [18F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001; 33: 1029–1035. 29. Kuang Y., Salem N. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Molecular рharmaceutics. 2010; 6: 2077–2092. 30. Trojan J., Schroeder O., Raedle J. Fluorine-18FDG positron emission tomography for imaging of hepatocellular carcinoma. Am. J. Gastroenterol. 1999; 94: 3314–3319. 31. Esschert J.W., Bieze M. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur. J. Nucl. Med. 2011; 38: 436–440. 32. Lee J., Paeng J. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J. Nucl. Med. 2009; 50: 682–687. 33. Kuang Y., Salem N. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]-choline: correlation with in vivo metabolic studies. J. Nucl. Med. 2011; 52: 98–106. 34. Bosman F., Carneiro F., Ruban R. Classification of tumors of the digestive system. 2010; 201–207.